Infectious diseases
Beyond COVID-19: BioNTech’s comprehensive approach to infectious diseases
At BioNTech, we are committed to continue addressing the global health challenges posed by infectious diseases. Leveraging our cutting-edge technology and expertise in immunology, we aim to develop innovative vaccines and therapeutics to overcome emerging and existing infectious diseases. Through targeted investments in mRNA- and protein-based infectious disease programs, we seek to fill substantial high and/or unmet medical needs, particularly in low- and middle-income countries.
We believe that the mRNA technology behind our COVID-19 vaccine has the potential to address a range of other infectious diseases.
Our infectious disease programs
As a science-driven company, we are dedicated to continuously exploring new opportunities and innovative approaches to effectively address infectious diseases, including the development of candidates in the indications outlined below.
Vaccine and therapeutic candidates for other high or unmet medical need indications
Our mRNA-based vaccines and vaccine candidates could offer several benefits in fighting infectious diseases, including shorter manufacturing times, which may enable the ability to quickly address emerging variants. Alongside efforts in COVID-19, tuberculosis and HIV, BioNTech is currently advancing other vaccine candidates, for example against Herpes Simplex Virus (“HSV”) and mpox.
Additionally, we are developing novel approaches to bacterial infections through synthetic lysin candidates which have the potential1 to improve the standard of care and tackle one of modern medicine’s greatest challenges: antibiotic resistance.
Source
1 Landlinger C et al., Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance. Antimicrobial Agents and Chemotherapy (2022)
